Arca
Skip to content

Congenital adrenal hyperplasia

Drug research and approvals for congenital adrenal hyperplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 30 studies of congenital adrenal hyperplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 1 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 30
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 30 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
May 21, 2026An open-label, long-term extension study to evaluate safety and efficacy of atumelnant in participants with congenital adrenal hyperplasiaATUMELNANT (CRN04894)Crinetics PharmaceuticalsPending
Mar 10, 2026A randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of atumelnant in adult participants with classic…ATUMELNANT (CRN04894)Crinetics PharmaceuticalsOngoing
May 14, 2021A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of spr001 (tildacerfont) in adult subjects with classic…TILDACERFONT (SPN001)SPRUCE BIOSCIENCE, INC.Closed
May 14, 2021A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of spr001 (tildacerfont) in reducing supraphysiologic glucocorticoid…TILDACERFONT (SPN001)SPRUCE BIOSCIENCE, INC.Closed
Mar 30, 2021A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of crinecerfont (nbi-74788) in pediatric subjects with classic…CRINECERFONT (NBI-74788)Neurocrine BiosciencesOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Dec 13, 2024Crenessityadjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with…Neurocrine Biosciences, Inc.Approved
Aug 18, 2025atumelnanttreatment of congenital adrenal hyperplasia (CAH)Crinetics Pharmaceuticals, Inc.Designated
May 12, 2025humanized anti-adrenocorticotropic hormone immunoglobulin…treatment of congenital adrenal hyperplasia (CAH)H. Lundbeck A/SDesignated
Aug 30, 2018adeno-associated virus vector expressing human…Treatment of congenital adrenal hyperplasia 21-hydroxylase deficiencyAdrenas Therapeutics IncDesignated
Nov 8, 2017corticotropin-releasing factor receptor-1 antagonist…Treatment of congenital adrenal hyperplasiaSpruce BiosciencesDesignated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 27, 2021EfmodyhydrocortisoneImmedica Pharma ABEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.